<?xml-stylesheet type="text/xsl" href="https://www.vetsurgeon.org/utility/feedstylesheets/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><title>Novartis secures marketing rights for Adequan&amp;#174; Equine</title><link>/b/veterinary-news/posts/4736</link><description> Novartis Animal Health Inc. has completed an agreement with Luitpold Pharmaceuticals, Inc. that grants marketing rights for Adequan&amp;#174; Equine to Novartis in all major equine markets outside the U.S. The first launch of Adequan&amp;#174; Equine by Novartis will</description><dc:language>en-US</dc:language><generator>Telligent Community 10</generator></channel></rss>